Arcturus: 'Hold' On Next-Gen ARCT-2601 OTC Candidate And Continued CF Advancement

🇺🇸 Seeking Alpha (US) —

AI Summary

The article maintains a Hold view on Arcturus, citing uncertainty around the next-generation ARCT-2601 over-the-counter candidate and ongoing cystic fibrosis program progress. It discusses the company's drug-development pipeline rather than reporting a clinical outcome.

Markets Health Arcturus ARCT-2601 drug development over-the-counter candidate cystic fibrosis Hold rating

Read original source →